Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 2 5Phase 1/2 1

Status

Completed 43Terminated 19Recruiting 13Active not recruiting 10Withdrawn 5Not yet recruiting 3Unknown 2

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Other hematologic neoplasm 1

Conditions

Neoplasms, Plasma Cell 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Stem Cell Transplantation × Clear all
NCT04220008 2024-01-12

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03881735 2021-03-10

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Roswell Park Cancer Institute

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT00968396 2013-04-05

Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡